Literature DB >> 15228773

Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation.

Sandi A Kwee1, Marc N Coel, John Lim, Jehoon P Ko.   

Abstract

BACKGROUND: Choline metabolism is often abnormal in malignant brain tumors.
METHODS: Brain positron emission tomography (PET) imaging with F-18 fluorocholine (FCH) was performed on 2 patients with intracranial lesions suspected to be high-grade malignant gliomas on the basis of magnetic resonance (MR) imaging and multivoxel 1H-MR spectroscopic imaging (MRSI) findings. Standardized uptake value (SUV) measurements on PET were compared with measurements of choline/creatine metabolite ratio on MRSI in corresponding regions. Brain biopsy revealed glioblastoma multiforme (GBM) in one case and demyelinating disease in the other.
RESULTS: In the case of GBM, the tumor demonstrated increased FCH uptake on PET. The mean and maximum SUV in areas of the tumor correlated with regional choline/creatine ratio measurements (r = 0.76, P < .001; r = 0.83, P < .001, respectively). In the case of tumefactive demyelinating lesions, the lesion demonstrated low FCH uptake, which did not correlate with choline/creatine ratio measurements.
CONCLUSIONS: Assessments of choline metabolism may aid in evaluating intracranial mass lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228773     DOI: 10.1177/1051228404264957

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  9 in total

1.  Total choline at 1H-MRS and [18F]-fluoromethylcholine uptake at PET.

Authors:  Sandi Kwee; Thomas Ernst
Journal:  Mol Imaging Biol       Date:  2010-08       Impact factor: 3.488

Review 2.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 3.  PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature.

Authors:  Koen Mertens; Dominique Slaets; Bieke Lambert; Marjan Acou; Filip De Vos; Ingeborg Goethals
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-11       Impact factor: 9.236

4.  ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.

Authors:  Manuel Gómez-Río; Nathalie Testart Dardel; Alicia Santiago Chinchilla; Antonio Rodríguez-Fernández; Gonzalo Olivares Granados; Raquel Luque Caro; Mercedes Zurita Herrera; Clara E Chamorro Santos; Pablo Lardelli-Claret; José M Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

Review 5.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

6.  Rodent rhabdomyosarcoma: comparison between total choline concentration at H-MRS and [18F]-fluoromethylcholine uptake at PET using accurate methods for collecting data.

Authors:  Denis Rommel; Anne Bol; Jorge Abarca-Quinones; Frank Peeters; Annie Robert; Daniel Labar; Christine Galant; Vincent Gregoire; Thierry Duprez
Journal:  Mol Imaging Biol       Date:  2009-11-25       Impact factor: 3.488

7.  Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats.

Authors:  Aditya Bansal; Wang Shuyan; Toshiko Hara; Robert A Harris; Timothy R Degrado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-09       Impact factor: 9.236

8.  Transbilayer phospholipids molecular imaging.

Authors:  Tarik Z Belhocine; Frank S Prato
Journal:  EJNMMI Res       Date:  2011-08-22       Impact factor: 3.138

9.  Detection Rate of 18F-Fluorethylcholine-PET/CT in relation to PSA Value in PCA Patients Referred with Biochemical Relapse.

Authors:  Mustafa Takesh; Khaldoun Odat Allh; Christian M Zechmann
Journal:  Contrast Media Mol Imaging       Date:  2020-08-11       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.